PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 16182764-2 2005 Standard primary immunosuppressive therapy after orthotopic liver transplantation (OLT) is based on a calcineurin-inhibitor (CNI): cyclosporine or tacrolimus. Tacrolimus 147-157 calcineurin binding protein 1 Homo sapiens 125-128 18929812-1 2008 OBJECTIVE: Tacrolimus, a potent calcineurin inhibitor, is a widely used immunosuppressant. Tacrolimus 11-21 calcineurin binding protein 1 Homo sapiens 32-53 18480504-1 2008 Tacrolimus, a calcineurin inhibitor, has become an increasingly valuable tool in the treatment of dermatological disorders during the last few years. Tacrolimus 0-10 calcineurin binding protein 1 Homo sapiens 14-35 18312164-2 2008 Over the last decade tacrolimus has become the calcineurin inhibitor of choice for the prevention of rejection in renal transplantation. Tacrolimus 21-31 calcineurin binding protein 1 Homo sapiens 47-68 16871590-4 2006 Immunosuppressive drugs used were tacrolimus (a calcineurin inhibitor) and its synergistic partners, rapamycin (a regulator of the mammalian target of rapamycin [mTOR]) and mycophenolate mofetil (an inosine monophosphate dehydrogenase inhibitor). Tacrolimus 34-44 calcineurin binding protein 1 Homo sapiens 48-69 16444593-4 2006 In addition, similar treatment of cardiomyocytes with 10 nM FK506, a calcineurin inhibitor, could also attenuate isoproterenol-induced apoptosis. Tacrolimus 60-65 calcineurin binding protein 1 Homo sapiens 69-90 19354332-1 2009 BACKGROUND: Tacrolimus, a calcineurin inhibitor, is an immunomodulating and anti-inflammatory drug that inhibits T-cell activation and production of cytokines. Tacrolimus 12-22 calcineurin binding protein 1 Homo sapiens 26-47 19652938-4 2009 The last mentioned immunological hypothesis has increasing importance, not at least based on the fact that the application of a topical calcineurin inhibitor (tacrolimus) improves the uremic pruritus. Tacrolimus 159-169 calcineurin binding protein 1 Homo sapiens 136-157 17854353-1 2007 Tacrolimus ointment is a topical calcineurin inhibitor (TCI) that was developed specifically for the treatment of atopic dermatitis (AD). Tacrolimus 0-10 calcineurin binding protein 1 Homo sapiens 33-54 17225017-1 2007 Tacrolimus ointment is a topical calcineurin inhibitor for the treatment of atopic dermatitis. Tacrolimus 0-10 calcineurin binding protein 1 Homo sapiens 33-54 16467444-2 2006 This study investigated whether tacrolimus, a novel calcineurin inhibitor, exerts fibrogenic effects to a similar extent. Tacrolimus 32-42 calcineurin binding protein 1 Homo sapiens 52-73 15773954-6 2005 An individualized approach to choice of calcineurin inhibitor, by which cyclosporine or tacrolimus are selected based on the patient"s particular risk profile, may thus help to reduce the toll of cardiovascular mortality among renal transplant recipients in the future. Tacrolimus 88-98 calcineurin binding protein 1 Homo sapiens 40-61 15837449-3 2005 Evidence from large-scale analyses of registry databases has shown that the calcineurin inhibitor, tacrolimus, is associated with approximately a 50% increase in the risk of NODM compared to the microemulsion formulation of cyclosporine (CsA); but to date, little robust evidence is available from clinical trials. Tacrolimus 99-109 calcineurin binding protein 1 Homo sapiens 76-97 15782552-7 2004 The newer calcineurin inhibitor tacrolimus is already widely used in the transplantation medicine while its effectiveness in clinical nephrology has to be tested. Tacrolimus 32-42 calcineurin binding protein 1 Homo sapiens 10-31 15621119-3 2004 Furthermore calcineurin inhibitor nephrotoxicity was exacerbated by rescue therapy with tacrolimus conversion. Tacrolimus 88-98 calcineurin binding protein 1 Homo sapiens 12-33 15251325-1 2004 Tacrolimus-induced toxicity is considered a dose-related side effect largely due to a direct action of this potent calcineurin inhibitor on its targets including the kidney and the pancreas. Tacrolimus 0-10 calcineurin binding protein 1 Homo sapiens 115-136 15001192-1 2004 BACKGROUND: Calcineurin inhibitor drugs (cyclosporine and tacrolimus) given to renal transplant recipients to prevent rejection are associated with an increased incidence of hypertension. Tacrolimus 58-68 calcineurin binding protein 1 Homo sapiens 12-33 14754647-3 2004 A topical formulation of tacrolimus, a macrolide calcineurin inhibitor, has recently been developed. Tacrolimus 25-35 calcineurin binding protein 1 Homo sapiens 49-70 15619640-1 2004 Calcineurin-inhibitor induced pain syndrome (CIPS) is a newly described entity with a characteristic feature of sudden onset of severe lower limb pain, and high levels of cyclosporine or tacrolimus may be involved in the pathogenesis. Tacrolimus 187-197 calcineurin binding protein 1 Homo sapiens 0-21 12777858-10 2003 The type of baseline calcineurin inhibitor (tacrolimus) and the age at OLT (beyond 6 years) were significantly associated with a better graft survival. Tacrolimus 44-54 calcineurin binding protein 1 Homo sapiens 21-42 12883227-8 2003 Dose reductions of tacrolimus in both study groups were reflected by concordant decreasing pharmacokinetic exposure parameters, which illustrates the common clinical practice of reducing the dose of calcineurin inhibitor as time elapses after transplantation. Tacrolimus 19-29 calcineurin binding protein 1 Homo sapiens 199-220 14720063-5 2002 Tacrolimus, a new calcineurin inhibitor, is increasingly employed as the primary immunosuppressive agent in lung transplant recipients. Tacrolimus 0-10 calcineurin binding protein 1 Homo sapiens 18-39 12387959-12 2002 Tacrolimus should be the first choice of calcineurin inhibitor for patients receiving their first liver graft. Tacrolimus 0-10 calcineurin binding protein 1 Homo sapiens 41-62 12914753-9 2003 Most interestingly, the calcineurin inhibitor, FK506, consistently inhibited CD3/CD28-induced CXCR6 down-regulation. Tacrolimus 47-52 calcineurin binding protein 1 Homo sapiens 24-45 12742481-1 2003 Calcineurin inhibitor drugs (CNI), primarily cyclosporine then tacrolimus, have been the centerpieces of maintenance immunosuppression for kidney transplantation since their introduction in the 1980s. Tacrolimus 63-73 calcineurin binding protein 1 Homo sapiens 0-21 12887261-15 2003 In the current immunosuppressive regimens, a calcineurin inhibitor, either tacrolimus or cyclosporin, is the essential basic standard immunosuppressant. Tacrolimus 75-85 calcineurin binding protein 1 Homo sapiens 45-66 11807435-4 2002 Pimecrolimus (ASM 981), a newer calcineurin inhibitor closely related to tacrolimus, is also being developed for atopic dermatitis therapy. Tacrolimus 73-83 calcineurin binding protein 1 Homo sapiens 32-53 9143223-0 1997 Calcineurin inhibitor, FK506, prevents reduction in the binding capacity of cyclic AMP-dependent protein kinase in ischemic gerbil brain. Tacrolimus 23-28 calcineurin binding protein 1 Homo sapiens 0-21 9858612-4 1999 FK506, another calcineurin inhibitor, shared the effect. Tacrolimus 0-5 calcineurin binding protein 1 Homo sapiens 15-36 11263551-8 2001 The Calcineurin-inhibitor Induced Pain Syndrome (CIPS) is a rare but severe side effect of cyclosporine or tacrolimus and is accurately diagnosed by its typical presentation, magnetic resonance imaging and bone scans. Tacrolimus 107-117 calcineurin binding protein 1 Homo sapiens 4-25 32640952-5 2020 The recent progress shows that the recommended strategy is to use as maintenance immunosuppressive therapy a combination of a calcineurin inhibitor (preferably tacrolimus) with an antiproliferative drug (preferably mycophenolate mofetil) with steroids that can be withdrawn early or late in low-risk children. Tacrolimus 160-170 calcineurin binding protein 1 Homo sapiens 126-147 34402788-1 2021 OBJECTIVE: The calcineurin inhibitor tacrolimus has been widely used to prevent allograft rejection after transplantation. Tacrolimus 37-47 calcineurin binding protein 1 Homo sapiens 15-36 34085919-1 2021 We report a case of neurotoxicity as a side effect of a calcineurin inhibitor (tacrolimus), which is used as an immunosuppressive drug after liver transplant. Tacrolimus 79-89 calcineurin binding protein 1 Homo sapiens 56-77 35428708-1 2022 OBJECTIVE: The calcineurin inhibitor tacrolimus has been approved in Japan for the treatment of interstitial pneumonia in patients with polymyositis (PM) and dermatomyositis (DM). Tacrolimus 37-47 calcineurin binding protein 1 Homo sapiens 15-36 33952632-2 2021 In this study, we tested the hypothesis that tacrolimus, a calcineurin inhibitor, prevents age-associated microstructural atrophy, which we measured using higher-order diffusion MRI, in the middle-aged beagle brain (n = 30, male and female). Tacrolimus 45-55 calcineurin binding protein 1 Homo sapiens 59-80 33952632-8 2021 In this study, we show that administration of the calcineurin inhibitor, tacrolimus, over one year prevents age and AD-associated microstructural changes in the hippocampus, parahippocampal cortex, and prefrontal cortex of the middle-aged beagle brain, with no noticeable adverse effects. Tacrolimus 73-83 calcineurin binding protein 1 Homo sapiens 50-71 33853841-2 2021 The vast majority of patients are treated with the calcineurin inhibitor tacrolimus as the primary agent in combination with mycophenolate, with or without corticosteroids. Tacrolimus 73-83 calcineurin binding protein 1 Homo sapiens 51-72 32664531-1 2020 Tacrolimus is a first-line calcineurin inhibitor (CNI) and an integral part of the immunosuppressive strategy in solid organ transplantation. Tacrolimus 0-10 calcineurin binding protein 1 Homo sapiens 27-48 31820394-1 2020 The calcineurin inhibitor tacrolimus is an effective immunosuppressant and is extensively used in solid organ transplantation. Tacrolimus 26-36 calcineurin binding protein 1 Homo sapiens 4-25 31049814-1 2020 BACKGROUND: Tacrolimus, a calcineurin inhibitor, is recommended by the recent guidelines from the Kidney Disease Improving Global Outcomes Group as the first-line treatment for steroid-resistant nephrotic syndrome (SRNS), but its clinical application in China is still limited. Tacrolimus 12-22 calcineurin binding protein 1 Homo sapiens 26-47 34809463-0 2021 Leveraging Fungal and Human Calcineurin-Inhibitor Structures, Biophysical Data, and Dynamics To Design Selective and Nonimmunosuppressive FK506 Analogs. Tacrolimus 138-143 calcineurin binding protein 1 Homo sapiens 28-49 34342024-1 2021 WHAT IS KNOWN AND OBJECTIVE: Tacrolimus (FK506), an effective and potent calcineurin inhibitor, is the cornerstone of immunosuppression after kidney transplantation. Tacrolimus 29-39 calcineurin binding protein 1 Homo sapiens 73-94 34342024-1 2021 WHAT IS KNOWN AND OBJECTIVE: Tacrolimus (FK506), an effective and potent calcineurin inhibitor, is the cornerstone of immunosuppression after kidney transplantation. Tacrolimus 41-46 calcineurin binding protein 1 Homo sapiens 73-94 34481645-1 2021 Calcineurin-inhibitor induced pain syndrome (CIPS) also called the "symmetrical bone syndrome" is a condition describing reversible lower extremity pain in patients after organ transplantation who are receiving calcineurin inhibitors, especially tacrolimus. Tacrolimus 246-256 calcineurin binding protein 1 Homo sapiens 0-21 34150686-1 2021 Background: The calcineurin inhibitor (CNI) tacrolimus (TAC) is a cornerstone agent in immunosuppressive therapy in pediatric liver transplantation (LTX). Tacrolimus 44-54 calcineurin binding protein 1 Homo sapiens 16-37 34150686-1 2021 Background: The calcineurin inhibitor (CNI) tacrolimus (TAC) is a cornerstone agent in immunosuppressive therapy in pediatric liver transplantation (LTX). Tacrolimus 56-59 calcineurin binding protein 1 Homo sapiens 16-37 33149056-1 2021 BACKGROUND: The calcineurin inhibitor tacrolimus is a narrow therapeutic index medication, which requires therapeutic drug monitoring to optimize dose on the basis of systemic exposure. Tacrolimus 38-48 calcineurin binding protein 1 Homo sapiens 16-37 35578566-1 2022 BACKGROUND Tacrolimus is a calcineurin inhibitor (CNI) commonly used as an immunosuppressant to prevent the rejection of organ transplants. Tacrolimus 11-21 calcineurin binding protein 1 Homo sapiens 27-48 33963666-7 2021 The calcineurin inhibitor (CNI) tacrolimus is the mainstay of immunosuppression but can result in AKI. Tacrolimus 32-42 calcineurin binding protein 1 Homo sapiens 4-25 32307148-1 2020 INTRODUCTION: After kidney transplantation (KTx) in patients with diagnosed cancers, calcineurin inhibitor tacrolimus (TAC) is replaced by sirolimus or everolimus (EV). Tacrolimus 107-117 calcineurin binding protein 1 Homo sapiens 85-106 32307148-1 2020 INTRODUCTION: After kidney transplantation (KTx) in patients with diagnosed cancers, calcineurin inhibitor tacrolimus (TAC) is replaced by sirolimus or everolimus (EV). Tacrolimus 119-122 calcineurin binding protein 1 Homo sapiens 85-106 31386765-2 2020 Tacrolimus (or FK506), a calcineurin inhibitor (CNI) introduced in field of transplantation in the 1990s, is the cornerstone of most immunosuppressive regimens in solid organ transplantation. Tacrolimus 0-10 calcineurin binding protein 1 Homo sapiens 25-46 31386765-2 2020 Tacrolimus (or FK506), a calcineurin inhibitor (CNI) introduced in field of transplantation in the 1990s, is the cornerstone of most immunosuppressive regimens in solid organ transplantation. Tacrolimus 15-20 calcineurin binding protein 1 Homo sapiens 25-46 32149187-1 2020 Tacrolimus is a reversible calcineurin inhibitor. Tacrolimus 0-10 calcineurin binding protein 1 Homo sapiens 27-48 30983820-3 2019 The performance of the calcineurin inhibitor tacrolimus in this clinical setting is insufficiently elucidated. Tacrolimus 45-55 calcineurin binding protein 1 Homo sapiens 23-44 31581670-0 2019 A Low Tacrolimus Concentration/Dose Ratio Increases the Risk for the Development of Acute Calcineurin Inhibitor-Induced Nephrotoxicity. Tacrolimus 6-16 calcineurin binding protein 1 Homo sapiens 90-111 30983748-0 2019 Loss of Subpodocytic Space Predicts Poor Response to Tacrolimus in Steroid-Resistant Calcineurin Inhibitor-Naive Adult-Onset Primary Focal Segmental Glomerulosclerosis. Tacrolimus 53-63 calcineurin binding protein 1 Homo sapiens 85-106 29479631-1 2019 The calcineurin inhibitor tacrolimus, cornerstone of most immunosuppressive regimens, is a drug with a narrow therapeutic window: underexposure can lead to allograft rejection and overexposure can result in an increased incidence of infections, toxicity and malignancies. Tacrolimus 26-36 calcineurin binding protein 1 Homo sapiens 4-25 30371942-1 2019 Tacrolimus, a calcineurin inhibitor, is a common immunosuppressant prescribed after organ transplantation and has notable inter- and intrapatient pharmacokinetic variability. Tacrolimus 0-10 calcineurin binding protein 1 Homo sapiens 14-35 30415182-1 2019 Calcineurin-inhibitor induced pain syndrome (CIPS) is a condition characterized by lower extremity pain in patients receiving tacrolimus or cyclosporine therapy following organ transplantation. Tacrolimus 126-136 calcineurin binding protein 1 Homo sapiens 0-21 29045960-1 2017 OBJECTIVE: Tacrolimus prolonged-release(PR) formulation is a new once-daily formulation of the calcineurin inhibitor tacrolimus, which is currently used in adult liver or kidney transplant patients,and is also gradually widely used in children with nephrotic syndrome.The present study was undertaken to preliminarily investigate the pharmacokinetic characteristics of tacrolimus PR in pediatric nephrotic syndrome recipients. Tacrolimus 11-21 calcineurin binding protein 1 Homo sapiens 95-116 29757021-1 2018 INTRODUCTION: Cornerstone immunosuppressive therapy currently relies on immediate-release tacrolimus, a calcineurin inhibitor (CNI) that is potentially nephrotoxic and is more diabetogenic than cyclosporine A. Tacrolimus 90-100 calcineurin binding protein 1 Homo sapiens 104-125 29904381-0 2018 The Calcineurin Inhibitor Tacrolimus Specifically Suppresses Human T Follicular Helper Cells. Tacrolimus 26-36 calcineurin binding protein 1 Homo sapiens 4-25 29904381-8 2018 Results: The calcineurin inhibitor (CNIs) tacrolimus specifically suppresses both LN Tfh cells and circulating Tfh cells, but not their regulatory counterparts or other CD4 T cell subsets. Tacrolimus 42-52 calcineurin binding protein 1 Homo sapiens 13-34 29594146-0 2018 Early Conversion from Tacrolimus to Belatacept in a Highly Sensitized Renal Allograft Recipient with Calcineurin Inhibitor-Induced de novo Post-Transplant Hemolytic Uremic Syndrome. Tacrolimus 22-32 calcineurin binding protein 1 Homo sapiens 101-122 30316389-1 2018 BACKGROUND: Inhibition of calcineurin inhibitor (CNI) metabolism with diltiazem reduces the dose of tacrolimus required to achieve its therapeutic blood concentration in kidney transplant recipients (KTRs). Tacrolimus 100-110 calcineurin binding protein 1 Homo sapiens 26-47 29298646-1 2018 BACKGROUND: The calcineurin inhibitor tacrolimus (Tac) is an integral part of the standard immunosuppressive regimen after renal transplantation (RTx). Tacrolimus 38-48 calcineurin binding protein 1 Homo sapiens 16-37 29045960-1 2017 OBJECTIVE: Tacrolimus prolonged-release(PR) formulation is a new once-daily formulation of the calcineurin inhibitor tacrolimus, which is currently used in adult liver or kidney transplant patients,and is also gradually widely used in children with nephrotic syndrome.The present study was undertaken to preliminarily investigate the pharmacokinetic characteristics of tacrolimus PR in pediatric nephrotic syndrome recipients. Tacrolimus 117-127 calcineurin binding protein 1 Homo sapiens 95-116 26473523-1 2016 BACKGROUND: Tacrolimus (Prograf, Advagraf, and FK-506) is the most commonly prescribed calcineurin inhibitor after kidney and liver transplantation. Tacrolimus 12-22 calcineurin binding protein 1 Homo sapiens 87-108 28508247-2 2017 Based mainly on the results of short-term studies, the calcineurin inhibitor tacrolimus prevails over the mammalian target of rapamycin (mTOR) inhibitors. Tacrolimus 77-87 calcineurin binding protein 1 Homo sapiens 55-76 27473149-7 2016 In cultured human cells, treatment with FK506 (tacrolimus), a calcineurin inhibitor, results in accumulation of pTDP species. Tacrolimus 40-45 calcineurin binding protein 1 Homo sapiens 62-83 27473149-7 2016 In cultured human cells, treatment with FK506 (tacrolimus), a calcineurin inhibitor, results in accumulation of pTDP species. Tacrolimus 47-57 calcineurin binding protein 1 Homo sapiens 62-83 27462157-0 2016 Decreased calcineurin immunoreactivity in the postmortem brain of a patient with schizophrenia who had been prescribed the calcineurin inhibitor, tacrolimus, for leukemia. Tacrolimus 146-156 calcineurin binding protein 1 Homo sapiens 123-144 29018183-7 2017 The calcineurin inhibitor, tacrolimus, was introduced on the fifth postoperative day. Tacrolimus 27-37 calcineurin binding protein 1 Homo sapiens 4-25 28280692-1 2017 The calcineurin inhibitor (CNI) tacrolimus (TAC) is an integral part of the immunosuppressive regimen after solid organ transplantation. Tacrolimus 32-42 calcineurin binding protein 1 Homo sapiens 4-25 28280692-1 2017 The calcineurin inhibitor (CNI) tacrolimus (TAC) is an integral part of the immunosuppressive regimen after solid organ transplantation. Tacrolimus 32-42 calcineurin binding protein 1 Homo sapiens 27-30 26473523-1 2016 BACKGROUND: Tacrolimus (Prograf, Advagraf, and FK-506) is the most commonly prescribed calcineurin inhibitor after kidney and liver transplantation. Tacrolimus 24-31 calcineurin binding protein 1 Homo sapiens 87-108 26473523-1 2016 BACKGROUND: Tacrolimus (Prograf, Advagraf, and FK-506) is the most commonly prescribed calcineurin inhibitor after kidney and liver transplantation. Tacrolimus 47-53 calcineurin binding protein 1 Homo sapiens 87-108 27109969-4 2016 Tacrolimus (TAC), calcineurin inhibitor, is one of immunosuppression pillar in organ transplantation and its action is strongly correlated with blood concentration and therefore the therapeutic drug monitoring is recommended in the guidelines. Tacrolimus 0-10 calcineurin binding protein 1 Homo sapiens 18-39 27003330-1 2016 BACKGROUND: The calcineurin inhibitor (CNI) tacrolimus (Tac) is an effective immunosuppressant used after liver transplantation (LTx), but is often associated with CNI nephrotoxicity. Tacrolimus 44-54 calcineurin binding protein 1 Homo sapiens 16-37 27500266-2 2016 Experimental studies indicate that an organ rinse with the calcineurin inhibitor tacrolimus before implantation protects against IRI. Tacrolimus 81-91 calcineurin binding protein 1 Homo sapiens 59-80 27109969-4 2016 Tacrolimus (TAC), calcineurin inhibitor, is one of immunosuppression pillar in organ transplantation and its action is strongly correlated with blood concentration and therefore the therapeutic drug monitoring is recommended in the guidelines. Tacrolimus 12-15 calcineurin binding protein 1 Homo sapiens 18-39 26160968-2 2015 Because sirolimus (SIR) and calcineurin inhibitor-either cyclosporine (CsA) or tacrolimus-have become more common as graft-versus-host disease (GVHD) prophylaxis, we are witnessing a higher frequency of this complication. Tacrolimus 79-89 calcineurin binding protein 1 Homo sapiens 28-49 26663079-7 2016 Finally, beta cell cytotoxicity of the calcineurin inhibitor and immunosuppressant tacrolimus (FK-506) was prevented by Npas4 overexpression. Tacrolimus 95-101 calcineurin binding protein 1 Homo sapiens 39-60 26824445-8 2016 This inverse association between MPA and SCSC persisted among OTRs with no history of azathioprine use, even after adjustment for simultaneous use of the calcineurin inhibitor tacrolimus (OR = 0.52, 95% CI 0.32-0.84). Tacrolimus 176-186 calcineurin binding protein 1 Homo sapiens 154-175 26575262-1 2015 The calcineurin inhibitor tacrolimus is the cornerstone of most immunosuppressive treatment protocols after solid organ transplantation in the United States. Tacrolimus 26-36 calcineurin binding protein 1 Homo sapiens 4-25 26031588-0 2015 Tacrolimus reduction with everolimus addition for calcineurin inhibitor-induced arteriolopathy in kidney allografts. Tacrolimus 0-10 calcineurin binding protein 1 Homo sapiens 50-71 26031588-1 2015 AIM: The aim of this study was to evaluate the effect of tacrolimus (TAC) reduction with everolimus (EVR) addition on the maintenance immunosuppression for the recipients with calcineurin inhibitor arteriolopathy (CNIA). Tacrolimus 57-67 calcineurin binding protein 1 Homo sapiens 176-197 25491283-0 2015 The calcineurin inhibitor tacrolimus as a new therapy in severe cherubism. Tacrolimus 26-36 calcineurin binding protein 1 Homo sapiens 4-25 26087255-1 2015 The direct effect of immunosuppressive drugs calcineurin inhibitor (Tacrolimus, TAC) and mTOR inhibitor (Sirolimus, SRL) on B cell activation, differentiation and proliferation is not well documented. Tacrolimus 68-78 calcineurin binding protein 1 Homo sapiens 45-66 25883698-6 2015 Calcineurin inhibitor, which includes cyclosporine, pimecrolimus and tacrolimus, impairs calcineurin-induced up-regulation of IL-2 expression, resulting in increased susceptibility to invasive fungal diseases. Tacrolimus 69-79 calcineurin binding protein 1 Homo sapiens 0-21 25255841-6 2014 EXPERT OPINION: Tacrolimus is a potent calcineurin inhibitor, an important pathway that regulates pancreatic development. Tacrolimus 16-26 calcineurin binding protein 1 Homo sapiens 39-60 25661468-7 2015 Here, we describe a very unusual neuropsychiatric side effect of tacrolimus and its resolution with another calcineurin inhibitor, cyclosporine, in an adolescent renal transplant recipient. Tacrolimus 65-75 calcineurin binding protein 1 Homo sapiens 108-129 25352392-1 2014 Extended-release tacrolimus (tacrolimus ER) [Advagraf( ); Astagraf XL( ); Graceptor( ); Prograf XL( )] is a once-daily formulation of the immunosuppressive calcineurin inhibitor, which is approved in many countries worldwide for the prophylaxis of transplant rejection in adult de novo kidney transplant recipients. Tacrolimus 17-27 calcineurin binding protein 1 Homo sapiens 156-177 25591474-8 2015 Similar results were obtained with the calcineurin inhibitor FK506, suggesting that most, but not all, effects on brain development and behavior are mediated by calcineurin inhibition. Tacrolimus 61-66 calcineurin binding protein 1 Homo sapiens 39-60 25340655-1 2014 The effective calcineurin inhibitor (CNI) tacrolimus (Tac) is an integral part of the standard immunosuppressive regimen after renal transplantation (RTx). Tacrolimus 42-52 calcineurin binding protein 1 Homo sapiens 14-35 25473571-3 2014 Tacrolimus, a calcineurin inhibitor, is one potential therapy. Tacrolimus 0-10 calcineurin binding protein 1 Homo sapiens 14-35 25165975-0 2014 The calcineurin inhibitor tacrolimus reduces proteinuria in membranous nephropathy accompanied by a decrease in angiopoietin-like-4. Tacrolimus 26-36 calcineurin binding protein 1 Homo sapiens 4-25 25165975-10 2014 In conclusion, this is the first demonstration that the calcineurin inhibitor tacrolimus can reduce Angptl4 in podocytes accompanied by a decrease in established proteinuria and promotion of podocyte repair in MN. Tacrolimus 78-88 calcineurin binding protein 1 Homo sapiens 56-77 25014506-2 2014 Calcineurin inhibitor (CNI) use is considered to play a major role in the development of CKD after LT. We studied the influence of single-nucleotide polymorphisms (SNPs) in the genes of the donor and recipient CNI-metabolizing enzyme CYP3A5 and the CNI-transporting ABCB1 on the development of CKD after LT. MATERIALS AND METHODS: Tacrolimus (Tac) predose concentrations at different time-points after transplantation and the CYP3A5 6986A>G and ABCB1 3435C>T SNPs were determined in 125 LT recipients and their respective donors to study the influence of Tac predose levels and genetics on the development of CKD. Tacrolimus 331-341 calcineurin binding protein 1 Homo sapiens 0-21 24935317-6 2014 The calcineurin inhibitor was tacrolimus in 98.9% of alemtuzumab patients, 98.2% of thymoglobulin patients, and 87.0% of the noninduced (P < .001). Tacrolimus 30-40 calcineurin binding protein 1 Homo sapiens 4-25 24249597-1 2014 The calcineurin inhibitor tacrolimus is the backbone of immunosuppressive drug therapy after solid organ transplantation. Tacrolimus 26-36 calcineurin binding protein 1 Homo sapiens 4-25 24097149-0 2013 [A case of calcineurin-inhibitor induced pain syndrome associated with tacrolimus therapy for ulcerative colitis]. Tacrolimus 71-81 calcineurin binding protein 1 Homo sapiens 11-32 23271170-1 2013 OBJECTIVES: A multicenter, randomized, double-blind, placebo-controlled study of the oral calcineurin inhibitor tacrolimus was performed in patients with early rheumatoid arthritis who had responded poorly to disease-modifying antirheumatic drugs (DMARDs), and factors related to suppression of joint destruction were investigated. Tacrolimus 112-122 calcineurin binding protein 1 Homo sapiens 90-111 24392311-5 2013 Potential improvements to the calcineurin inhibitor class include a prolonged release tacrolimus formulation and voclosporin, a cyclosporine analog. Tacrolimus 86-96 calcineurin binding protein 1 Homo sapiens 30-51 24097149-6 2013 We suspected calcineurin-inhibitor induced pain syndrome (CIPS) due to tacrolimus therapy. Tacrolimus 71-81 calcineurin binding protein 1 Homo sapiens 13-34 23921892-0 2013 Evolution to twice daily bolus intravenous tacrolimus: optimizing efficacy and safety of calcineurin inhibitor delivery early post lung transplant. Tacrolimus 43-53 calcineurin binding protein 1 Homo sapiens 89-110 22660906-1 2013 Tacrolimus, a reversible calcineurin inhibitor, is known for its diabetogenic potential. Tacrolimus 0-10 calcineurin binding protein 1 Homo sapiens 25-46 23947183-3 2013 Tacrolimus, a calcineurin inhibitor, is usually used for immunosuppressive therapy after transplantation. Tacrolimus 0-10 calcineurin binding protein 1 Homo sapiens 14-35 23622581-1 2013 BACKGROUND: Tacrolimus, a calcineurin inhibitor, is prescribed to prevent allograft rejection in renal transplantation. Tacrolimus 12-22 calcineurin binding protein 1 Homo sapiens 26-47 22706623-1 2013 BACKGROUND AND OBJECTIVES: Tacrolimus(PR) is a new prolonged-release once-daily formulation of the calcineurin inhibitor tacrolimus, currently used in adult transplant patients. Tacrolimus 27-37 calcineurin binding protein 1 Homo sapiens 99-120 23227980-2 2013 Specifically, the use of the calcineurin inhibitor tacrolimus is problematic because of a narrow therapeutic range, a high interindividual variability of trough levels, and multiple interactions with combination antiretroviral therapy (cART). Tacrolimus 51-61 calcineurin binding protein 1 Homo sapiens 29-50 23497558-3 2013 Experimental data have shown that the calcineurin inhibitor tacrolimus exerts protective effects on hepatic IRI when applied intravenously or directly as a hepatic rinse. Tacrolimus 60-70 calcineurin binding protein 1 Homo sapiens 38-59 22706623-1 2013 BACKGROUND AND OBJECTIVES: Tacrolimus(PR) is a new prolonged-release once-daily formulation of the calcineurin inhibitor tacrolimus, currently used in adult transplant patients. Tacrolimus 121-131 calcineurin binding protein 1 Homo sapiens 99-120 23677660-1 2012 Calcineurin inhibitor encephalopathy (CIE) is a rare condition occurring in patients who are undergoing treatment with drugs from the calcineurin inhibitor (CI) family of immunosuppressants, either cyclosporine (CsA) or tacrolimus (TAC, FK506). Tacrolimus 220-230 calcineurin binding protein 1 Homo sapiens 0-21 23560366-1 2013 Tacrolimus, a calcineurin inhibitor, is a potent immunosuppressive agent used by a majority of transplanters across the globe. Tacrolimus 0-10 calcineurin binding protein 1 Homo sapiens 14-35 23291669-1 2013 OBJECTIVE: The calcineurin inhibitor tacrolimus has been shown to be safe and effective as salvage therapy for steroid-refractory ulcerative colitis (UC). Tacrolimus 37-47 calcineurin binding protein 1 Homo sapiens 15-36 23677660-1 2012 Calcineurin inhibitor encephalopathy (CIE) is a rare condition occurring in patients who are undergoing treatment with drugs from the calcineurin inhibitor (CI) family of immunosuppressants, either cyclosporine (CsA) or tacrolimus (TAC, FK506). Tacrolimus 220-230 calcineurin binding protein 1 Homo sapiens 134-155 23677660-1 2012 Calcineurin inhibitor encephalopathy (CIE) is a rare condition occurring in patients who are undergoing treatment with drugs from the calcineurin inhibitor (CI) family of immunosuppressants, either cyclosporine (CsA) or tacrolimus (TAC, FK506). Tacrolimus 220-230 calcineurin binding protein 1 Homo sapiens 38-40 23677660-1 2012 Calcineurin inhibitor encephalopathy (CIE) is a rare condition occurring in patients who are undergoing treatment with drugs from the calcineurin inhibitor (CI) family of immunosuppressants, either cyclosporine (CsA) or tacrolimus (TAC, FK506). Tacrolimus 232-235 calcineurin binding protein 1 Homo sapiens 0-21 23677660-1 2012 Calcineurin inhibitor encephalopathy (CIE) is a rare condition occurring in patients who are undergoing treatment with drugs from the calcineurin inhibitor (CI) family of immunosuppressants, either cyclosporine (CsA) or tacrolimus (TAC, FK506). Tacrolimus 232-235 calcineurin binding protein 1 Homo sapiens 38-40 23677660-1 2012 Calcineurin inhibitor encephalopathy (CIE) is a rare condition occurring in patients who are undergoing treatment with drugs from the calcineurin inhibitor (CI) family of immunosuppressants, either cyclosporine (CsA) or tacrolimus (TAC, FK506). Tacrolimus 237-242 calcineurin binding protein 1 Homo sapiens 0-21 23677660-1 2012 Calcineurin inhibitor encephalopathy (CIE) is a rare condition occurring in patients who are undergoing treatment with drugs from the calcineurin inhibitor (CI) family of immunosuppressants, either cyclosporine (CsA) or tacrolimus (TAC, FK506). Tacrolimus 237-242 calcineurin binding protein 1 Homo sapiens 38-40 30532941-10 2012 This case demonstrates that conversion to the extended-release formulation of tacrolimus from other calcineurin inhibitor preparations is a reasonable choice to consider in the management of compromised immunosuppressive therapy adherence in heart transplant patients during the late posttransplant period. Tacrolimus 78-88 calcineurin binding protein 1 Homo sapiens 100-121 22729026-1 2012 PURPOSE OF REVIEW: The purpose of the review is to review the pathophysiology, available data, and our current recommendations for calcineurin inhibitor (cyclosporine and tacrolimus) treatment in antihistamine refractory chronic idiopathic urticaria (CIU) patients. Tacrolimus 171-181 calcineurin binding protein 1 Homo sapiens 131-152 22221776-2 2012 To our knowledge, there have been no prospective trials examining the use of oral tacrolimus, a calcineurin inhibitor, in AD. Tacrolimus 82-92 calcineurin binding protein 1 Homo sapiens 96-117 22476221-6 2012 Both protease inhibitors can modify the levels of drugs metabolized by the CYP3A/4 pathway, and in posttransplant patients, the protease inhibitors increase the levels of cyclosporine and tacrolimus, with the magnitude of the drug-drug interactions varying with protease inhibitor and type of calcineurin inhibitor (CNI). Tacrolimus 188-198 calcineurin binding protein 1 Homo sapiens 293-314 22476221-6 2012 Both protease inhibitors can modify the levels of drugs metabolized by the CYP3A/4 pathway, and in posttransplant patients, the protease inhibitors increase the levels of cyclosporine and tacrolimus, with the magnitude of the drug-drug interactions varying with protease inhibitor and type of calcineurin inhibitor (CNI). Tacrolimus 188-198 calcineurin binding protein 1 Homo sapiens 316-319 22310591-9 2012 Calcineurin inhibitor toxicity, which showed higher tendency in patients with CYP3A5*1 alleles, might be associated with higher tacrolimus dose per kilogram. Tacrolimus 128-138 calcineurin binding protein 1 Homo sapiens 0-21 20726688-5 2010 Amongst the last is the calcineurin inhibitor (CNI) (cyclosporine A (CsA) and tacrolimus)-related nephrotoxicity. Tacrolimus 78-88 calcineurin binding protein 1 Homo sapiens 24-45 21672049-2 2011 Tacrolimus, a very potent and effective calcineurin inhibitor, was selected because of its ability to ameliorate I/R injury. Tacrolimus 0-10 calcineurin binding protein 1 Homo sapiens 40-61 20937549-0 2011 Bidirectional immunoregulation of calcineurin inhibitor tacrolimus on FOXP3 transcription? Tacrolimus 56-66 calcineurin binding protein 1 Homo sapiens 34-55 21094806-1 2010 OBJECTIVE: The present study was designed to investigate the effect of low-dose calcineurin inhibitor (CNI) tacrolimus combined with a mammalian target of rapamycin (mTOR) inhibitor on renal function in transplant recipients without allograft nephropathy. Tacrolimus 108-118 calcineurin binding protein 1 Homo sapiens 80-101 21094806-1 2010 OBJECTIVE: The present study was designed to investigate the effect of low-dose calcineurin inhibitor (CNI) tacrolimus combined with a mammalian target of rapamycin (mTOR) inhibitor on renal function in transplant recipients without allograft nephropathy. Tacrolimus 108-118 calcineurin binding protein 1 Homo sapiens 103-106 20842569-11 2010 The calcineurin inhibitor (CNI) tacrolimus is being used as the cornerstone of maintenance therapy in lieu of cyclosporine in more and more centers. Tacrolimus 32-42 calcineurin binding protein 1 Homo sapiens 4-25 19714314-1 2009 Tacrolimus is a widely used T cell targeted immunosuppressive drug, known as a calcineurin inhibitor. Tacrolimus 0-10 calcineurin binding protein 1 Homo sapiens 79-100 20528886-0 2010 The calcineurin inhibitor tacrolimus allows the induction of functional CD4CD25 regulatory T cells by rabbit anti-thymocyte globulins. Tacrolimus 26-36 calcineurin binding protein 1 Homo sapiens 4-25 20526235-10 2010 CONCLUSIONS: High early tacrolimus dose requirements, predominantly but not exclusively encountered in CYP3A5*1 expressers, are associated with the development of calcineurin inhibitor-related nephrotoxicity, especially in recipients who continue corticosteroid therapy. Tacrolimus 24-34 calcineurin binding protein 1 Homo sapiens 163-184 20571464-1 2010 Chronic calcineurin inhibitor (CNI)-induced nephrotoxicity is associated with prolonged use of cyclosporine and tacrolimus and has been observed after all types of transplantation, as well as during treatment of autoimmune disease. Tacrolimus 112-122 calcineurin binding protein 1 Homo sapiens 8-29 20480792-4 2010 In this article, the authors review clinical trials using tacrolimus ointment, a topical calcineurin inhibitor, to treat adult and pediatric patients with AD over a wide range of disease severity focusing on its efficacy in rapidly reducing pruritus. Tacrolimus 58-68 calcineurin binding protein 1 Homo sapiens 89-110 20373462-2 2010 Recent findings have suggested that the calcineurin inhibitor tacrolimus (Tac), unlike cyclosporine A (CsA), interferes with the antiviral activity of interferon-alpha (IFN-alpha) in vitro. Tacrolimus 62-72 calcineurin binding protein 1 Homo sapiens 40-61 20373462-2 2010 Recent findings have suggested that the calcineurin inhibitor tacrolimus (Tac), unlike cyclosporine A (CsA), interferes with the antiviral activity of interferon-alpha (IFN-alpha) in vitro. Tacrolimus 74-77 calcineurin binding protein 1 Homo sapiens 40-61 20080907-0 2010 Tacrolimus, a calcineurin inhibitor, overcomes treatment unresponsiveness mediated by P-glycoprotein on lymphocytes in refractory rheumatoid arthritis. Tacrolimus 0-10 calcineurin binding protein 1 Homo sapiens 14-35 20080907-1 2010 OBJECTIVE: Tacrolimus, a calcineurin inhibitor, is used for treatment of rheumatoid arthritis (RA). Tacrolimus 11-21 calcineurin binding protein 1 Homo sapiens 25-46 20197746-13 2010 Efficacy of calcineurin inhibitor combinations also vary based on the type used and UV light combined, with tacrolimus being more effective with excimer laser. Tacrolimus 108-118 calcineurin binding protein 1 Homo sapiens 12-33 21436979-3 2009 Tacrolimus, a calcineurin inhibitor, not only complements existing treatment options but also overcomes some of the drawbacks of topical steroid therapy when given topically and thus meets the long-term needs of patients in preventing disease progression. Tacrolimus 0-10 calcineurin binding protein 1 Homo sapiens 14-35 21436979-5 2009 The recent proactive use of topical tacrolimus may emphasize a long-term benefit of this calcineurin inhibitor for AD treatment. Tacrolimus 36-46 calcineurin binding protein 1 Homo sapiens 89-110 20175769-1 2010 BACKGROUND: The calcineurin inhibitor tacrolimus and the anti-TNF-antibody infliximab are established options in steroid-refractory ulcerative colitis (UC). Tacrolimus 38-48 calcineurin binding protein 1 Homo sapiens 16-37 19335686-2 2009 But the clinical efficacy of topical tacrolimus, a newly developed calcineurin inhibitor on seborrheic dermatitis, is not well investigated yet. Tacrolimus 37-47 calcineurin binding protein 1 Homo sapiens 67-88 19454720-2 2009 The objective of this study was to comprehensively investigate FcepsilonRI-mediated chemokine induction in human mast cells and the effect of a corticosteroid (dexamethasone) and a calcineurin inhibitor (FK506). Tacrolimus 204-209 calcineurin binding protein 1 Homo sapiens 181-202